Treatment with duloxetine in adults and the incidence of cardiovascular events

Journal of Clinical Psychopharmacology

Volumn 32, Issue 1, 2012, Pages 23-30

  Xue, Fei ^a   Strombom, Indiana ^b   Turnbull, Bruce ^c   Zhu, Shao ^c   Seeger, John ^c,d  

^a AMGEN INC   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Ingenix i3 Drug Safety   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cardiovascular events; duloxetine; pharmacoepidemiology; safety

Indexed keywords

DULOXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; DEPRESSION; DRUG SAFETY; FOLLOW UP; HEART ARRHYTHMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSIVE CRISIS; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; SIDE EFFECT; SUDDEN DEATH;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CAUSE OF DEATH; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYCLOHEXANOLS; DEPRESSIVE DISORDER; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSURANCE CLAIM REVIEW; MALE; PROPENSITY SCORE; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; THIOPHENES; UNITED STATES; YOUNG ADULT;

EID: 84855343952     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31823fb238     Document Type: Article

References (29)

1. Russell IJ, Mease PJ, Smith TR, et al. Efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136:432-444.
2. Wernicke J, Lledó A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30:437-455. (Pubitemid 46740340)
3. Detke M, Iyengar S, Henck JW, et al. Cardiovascular Effects of Duloxetine: Preclinical and Clinical Findings. American College of Neuropsychopharmacology 44th Annual Meeting; 2005 Dec 11-15; Waikoloa, HI.
4. Derby MA, Zhang L, Chappell JC, et al. The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate. J Cardiovasc Pharmacol. 2007;49(6):384-393. (Pubitemid 47000313)
5. Zhang L, Chappell J, Gonzales CR et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol. 2007;49:146-153. (Pubitemid 46579948)
6. Roose SP. Depression, anxiety, and the cardiovascular system: the psychiatrist's perspective. J Clin Psychiatry. 2001;62(suppl 8):19-22.
7. Roose SP, Miyazaki M. Pharmacologic treatment of depression in patients with heart disease. Psychosom Med. 2005;67(suppl 1): S54-S57. (Pubitemid 40721034)
8. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10:732-747. (Pubitemid 41443048)
9. Schleifer SJ, Macari-Hinson MM, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med. 1989;149:1785-1789. (Pubitemid 19200834)
10. Forrester AW, Lipsey JR, Teitelbaum ML, et al. Depression following myocardial infarction. Int J Psychiatry Med. 1992;22:33-46.
11. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA. 1993;270:1819-1825. (Pubitemid 23301435)
12. Anda R, Williamson D, Jones D, et al. Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of U.S. adults. Epidemiology. 1993;4:285-294. (Pubitemid 23199705)
13. Appels A, Kop WJ, Schouten E. The nature of the depressive symptomatology preceding myocardial infarction. Behav Med. 2000;26:86-89. (Pubitemid 32104059)
14. Barefoot JC, Helms MJ, Mark DB, et al. Depression and long-term mortality risk in patients with coronary artery disease. Am J Cardiol. 1996;78:613-617. (Pubitemid 126658611)
15. Ford DE, Mead LA, Chang PP, et al. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med. 1998;158:1422-1426. (Pubitemid 28317757)
16. Hallstrom T, Lapidus L, Bengtsson C, et al. Psychosocial factors and risk of ischaemic heart disease and death in women: a twelve-year follow-up of participants in the population study of women in Gothenburg, Sweden. J Psychosom Res. 1986;30:451-459. (Pubitemid 17170044)
17. Mendes de Leon CF, Krumholz HM, Seeman TS, et al. Depression and risk of coronary heart disease in elderly men and women: New Haven EPESE, 1982-1991. Established populations for the epidemiologic studies of the elderly. Arch Intern Med. 1998;158:2341-2348. (Pubitemid 28536487)
18. Pratt LA, Ford DE, Crum RM, et al. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation. 1996;94:3123-3129.
19. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1988;70:41-55.
21. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333. (Pubitemid 29383480)
22. Rothman KJ, Ray W. Should cases with a 'known' cause of their disease be excluded from study? (commentary). Pharmacoepidemiol Drug Saf. 2002;11:11-14. (Pubitemid 34269591)
23. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf. 2006;15: 291-303. (Pubitemid 43797117)
24. Roose SP, Dalack GW, Woodring S. Death, depression, and heart disease. J Clin Psychiatry. 1991;52(suppl):34-39.
25. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med. 2004;66:305-315. (Pubitemid 38668397)
26. Cole JA, Norman H, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109:339-346. (Pubitemid 46197426)
27. Velentgas P, West W, Cannuscio CC, et al. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. Pharmacoepidemiol Drug Saf. 2006;15:641-652. (Pubitemid 44404662)
28. Eng PM, Seeger JD, Loughlin J, et al. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. Pharmacoepidemiol Drug Saf. 2008;17:297-305. (Pubitemid 351404040)
29. Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson. Med Care. 2007;45(suppl 2):S143-S148.